NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS
申请人:Lee Kwang-Ok
公开号:US20100179120A1
公开(公告)日:2010-07-15
The present invention provides a novel amide derivative and a pharmaceutically acceptable salt thereof which selectively and effectively inhibits the growth of cancer cells induced by the overexpression of an epidermal growth factor receptor and also prevents the development of drug resistance caused by the mutation of EGFR tyrosine kinase, and a pharmaceutical composition comprising same as an active ingredient.
The present invention relates to a series of quinazoline compounds, especially compounds as represented by formula (I), isomers thereof or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and use thereof as Pan-HER tyrosine kinase inhibitors.
本发明涉及一系列喹唑啉化合物,特别是由式(I)表示的化合物、其异构体或其药学上可接受的盐、其药物组合物,以及其作为泛 HER 酪氨酸激酶抑制剂的用途。
[EN] USE OF QUINAZOLINE DERIVATIVE IN PREPARATION OF DRUG FOR TREATING NASOPHARYNGEAL CARCINOMA<br/>[FR] UTILISATION D'UN DÉRIVÉ DE QUINAZOLINE DANS LA PRÉPARATION D'UN MÉDICAMENT POUR LE TRAITEMENT DU CARCINOME NASOPHARYNGÉ<br/>[ZH] 喹唑啉衍生物在制备治疗鼻咽癌药物中的应用
[EN] NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS<br/>[FR] NOUVEAU DÉRIVÉ D'AMIDE POUVANT INHIBER LA CROISSANCE DE CELLULES CANCÉREUSES
申请人:HANMI PHARM IND CO LTD
公开号:WO2008150118A2
公开(公告)日:2008-12-11
[EN] The present invention provides a novel amide derivative and a pharmaceutically acceptable salt thereof which selectively and effectively inhibits the growth of cancer cells induced by the overexpression of an epidermal growth factor receptor and also prevents the development of drug resistance caused by the mutation of EGFR tyrosine kinase, and a pharmaceutical composition comprising same as an active ingredient. [FR] La présente invention concerne un nouveau dérivé d'amide, et son sel pharmaceutiquement acceptable, qui peut inhiber sélectivement et efficacement la croissance de cellules cancéreuses induites par la surexpression d'un récepteur du facteur de croissance épidermique, mais aussi empêcher le développement de la résistance au médicament causée par la mutation de la tyrosine kinase EGFR. L'invention concerne également une composition pharmaceutique comprenant ce dérivé coomme principe actif.